

Cancer Chemotherapy and Pharmacology

Volume 15 1985

Edited by

S.K. CARTER and T. McELWAIN

Editorial Board

M. Acton Menlo Park
P. Alberto Geneva
R. H. Blum New York
M. Boiron Paris
H. Calvert Sutton
R. L. Comis Syracuse
T. Connors Carshalton
R. C. Coombes Sutton
S. Eckhardt Budapest
B. W. Fox Manchester
R. M. Fox Sydney
S. Garattini Milano
M. Ghione Milano

H. H. Hansen Copenhagen
K. Karrer Vienne
D. L. Kisner Bethesda
J. Laszlo Durham
R. B. Livingston Seattle
J. S. Macdonald Bethesda
J. G. McVie Amsterdam
F. M. Muggia New York
M. Ogawa Tokyo
P. Martin Marseille
S. Pavlovsky Buenos Aires
P. Potier Gif-sur-Yvette
P. Reizenstein Stockholm

E. Robinson Haifa
M. Rozencweig Brussels
C. G. Schmidt Essen
H. J. Senn St. Gallen
J. F. Smyth Edinburgh
A. Trouet Brussels
S. Tsukagoshi Tokyo
U. Umezawa Tokyo
F. A. Valeriote Detroit
L. M. van Putten Rijswijk
P. Wilkinson Manchester
G. Wu Huan-Hsin Peking



Springer International

Cancer Chemotherapy and Pharmacology

This journal was founded in 1978. Editors: S. K. Carter, T. McElwain. Published by Springer International.

Copyright

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for photocopies in the USA: Photocopies may be made for personal or inhouse use beyond the limitations stipulated under Section 107 or 108 of U.S. Copyright Law, provided a fee is paid. This fee is US \$ 0.20 per page, or a minimum of US \$ 1.00 if an article contains fewer than five pages. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0340-7004, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

Other regulations: Authors publishing in this journal can, under certain conditions, benefit from library and photocopy fees collected by VG WORT. Authors of German nationality and those resident in the Federal Republic of Germany or Berlin (West), as well as citizens of Austria, Switzerland and member countries of the European Community, may apply to Verwertungsgesellschaft WORT, Abteilung Wissenschaft, Goethestraße 49, D-8000 München 2, for detailed information.

Printed in Germany by Ernst Kieser GmbH Graphischer Betrieb, D-8902 Neusäß

© by Springer-Verlag Berlin Heidelberg 1985


Contents of volume 15

- Adam AM, Bradbrook ID, Rogers HJ: High-performance liquid chromatographic assay for simultaneous estimation of amino-glutethimide and acetylaminoglutethimide in biological fluids 176
- Adenis L, see Hecquet, et al. 310
- Ahmed NK, see Vasanthakumar G 35
- Ahmedzai S, see Cunningham D, et al. 303
- Ames MM, see Miller K, et al. 49
- Antoniw P, see Brindley CJ, et al. 66
- Aoki K, see Iwamoto Y, et al. 228
- Arbuck SG, see Pendyala L, et al. 203
- Ardalan B, Chandrasekaran B, Hrishikeshan HJ: Biochemical mechanisms for the scheduled synergism of (α S, 5S)-2 amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid and 5-fluorouracil in P388 leukemia 44
- Armand JP, see Bernadou J, et al. 63
- Ashley S, see Perez DJ, et al. 278
- Baba T, see Iwamoto Y, et al. 228
- Bachur NR, see Dodion P, et al. 153
- Bagshawe KD, see Brindley CJ, et al. 66
- Banham SW, see Cunningham D, et al. 303
- Barbor PRH, see Pinkerton CR, et al. 258
- Barbet J, see Bertault-Pérès P, et al. 76
- Baurain R, see Ninana J, et al. 263
- Beksac M, Peterson C, Reizenstein P: Decreased retention of vinca alkaloids in chronic lymphatic leukemia cells from refractory patients 72
- Bernadou J, Monserrat B, Roche H, Armand J-P, Paoletti C, Meunier B: Evidence for electrophilic properties of *N*²-methyl-9-hydroxy elliptinium acetate (Celiptium) from human biliary metabolites 63
- Bertault-Pérès P, Maraminchi D, Carcassonne Y, Cano JP, Barbet J: Clinical pharmacokinetics of cyclosporin A in bone marrow transplantation patients 76
- Bielack S, see Erttmann R, et al. 101
- Bollag W, see Hartmann HR 141
- Bonnetterre J, see Hecquet B, et al. 310
- Booker L, see Brownman GP, et al. 105
- Booker L, see Brownman GP, et al. 111
- Boulet L, see Dufour M, et al. 125
- Bowman A, see Pinkerton CR, et al. 258
- Bradbrook ID, see Adam AM, et al. 176
- Brasch H, see Iven H, et al. 115
- Brindley CJ, Antoniw P, Newlands ES, Bagshawe KD: Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratoma 66
- Brownman GP, Booker L, Spiegel P: Differential calcium leucovorin protection of human lymphoid cell lines from methotrexate 105
- Brownman GP, Spiegel P, Booker L, Rosowsky A: Comparison of leucovorin protection from variety of antifolates in human lymphoid cell lines 111
- Brunet R, see Bui NB, et al. 82
- Buck M, Kovach JS: Blood and tissue concentrations of Bisantrone measured by a simple fluorometric assay 40
- Bugat R, see Canal P, et al. 149
- Buck M, see Kovach JS, et al. 192
- Bui NB, Chauvergne J, Hocke C, Durand M, Brunet R, Coindre J-M: Analysis of a series of sixty soft tissue sarcomas in adults treated with a cyclophosphamide-vincristine-adriamycin-dacarbazine (CYVADIC) combination 82
- Burghouts JTM, see Wagener DJTh, et al. 86
- Burnett AK, see Cunningham D, et al. 303
- Cadman E, see Danhauser LL, et al. 214
- Caldwell J, see Gilchrist NL, et al. 290
- Canal P, Bugat R, Michel C, Roche H, Soula G, Combes PF: Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma 149
- Cano JP, see Bertault-Pérès P, et al. 76
- Carcassonne Y, see Bertault-Pérès, et al. 76
- Casper ES, Mittelman A, Kelson D, Young CW: Phase I clinical trial of fludarabine phosphate (F-ara-AMP) 233
- Catino JJ, Francher DM, Edinger KJ, Stringfellow DA: A microtitre cytotoxicity assay useful for the discovery of fermentation-derived antitumor agents 240
- Caty A, see Hecquet B, et al. 310
- Chandrasekaran B, see Ardalan B, et al. 44
- Chauvergne J, see Bui NB, et al. 82
- Clarke S, see Perez DJ, et al. 278
- Cohen BE, see Gutierrez PL, et al. 185
- Cohen PS, Smith SD: In vitro and in vivo chemotherapy screening of the divalent cation chelator 1,10-orthophenanthroline 6
- Coindre JM, see Bui NB, et al. 82
- Combes PF, see Canal P, et al. 149
- Coombes RC, see Waxmann JH, et al. 171
- Coombes RC, see Perez DJ, et al. 278
- Corden et al: Clinical pharmacology of high-dose cisplatin. *Cancer Chemother Pharmacol* 14: 38-41 (Letter to the editor) 183
- Cornu G, see Ninana J, et al. 263
- Creagan ET, see Edmonson JH, et al. 181
- Creaven PJ, see Pendyala L, et al. 203
- Cunningham D, see Gilchrist NL, et al. 290
- Cunningham D, Banham SW, Hutcheon AH, Dorward A, Ahmedzai S, Tansey P, Soukop M, Stevenson RD, Stack BR, Kaye SB, Lucie N, Burnett AK: High-dose cyclophosphamide and VP 16 as late dosage intensification therapy for small cell carcinoma of lung 303
- Dahl O, see Fossá SD, et al. 161
- Dam FE van, see Wagener DJTh, et al. 86
- Danhauser LL, Heimer R, Cadman E: Lack of enhanced cytotoxicity of cultured L1210 cells using folic acid in combination with sequential methotrexate and fluorouracil 214
- Danigel H, Pfützer KH, Jungclas H, Schmidt L, Dellbrügge J: Drug monitoring of etoposide (VP16-213). I. A combined method of liquid chromatography and mass spectrometry 121
- Davis TA, see Gutierrez PL, et al. 185
- Dellbrügge J, see Danigel H, et al. 121
- Demaille A, see Hecquet B, et al. 310
- Dodion P, Egorin MJ, Riggs CE Jr, Ferraro TA, Tamburini JM, Bachur NR: Comparative murine metabolism and disposition of class II anthracycline antibiotics 153
- Dohke Y, see Kojima T, et al. 268
- Doorenbos H, see Veelen H van, et al. 167
- Dorman EB, see Morton RP, et al. 283
- Dorward A, see Cunningham D, et al. 303
- Dufour M, Panasci LC, Germain JSt, Boulet L: Effects of amino acids on the transport and cytotoxicity of melphalan by human bone marrow cells and human tumor cells 125
- Durand M, see Bui NB, et al. 82
- Eden OB, see Pinkerton CR, et al. 258
- Edinger KJ, see Catino JJ, et al. 240
- Edmonson JH, Long HJ, Richardson RL, Creagan ET, Green SJ: Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas 181
- Egorin MJ, see Dodion P, et al. 153
- Egorin MJ, see Gutierrez PL, et al. 185
- Ellis ME, Weiss RB, Kuperminc M: Nephrotoxicity of lomustine. A case report and literature review 174
- Engster H, see Iven H, et al. 115
- Erttmann R, Bielack S, Landbeck G: Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy 101

- Falkeson G, see Vorobiof DA, et al. 253
 Ferraro TA, see Dodion P, et al. 153
 Fitch W, see Gilchrist NL, et al. 290
 Florence AT, see Halbert GW, et al. 223
 Ford J, see Panasci L, et al. 164
 Forrest GJ, see Gilchrist NL, et al. 290
 Fossá SD, Dahl O, Hoel R, Heier M, Loeb M: Doxifluridine (5'-dFUrD) in patients with advanced colorectal carcinoma. A phase II study 161
 Fournier C, see Hecquet B, et al. 310
 Francher DM, see Catino JJ, et al. 240
 Fridkin M, see Ramu A, et al. 31
 Fürtterer G, see Mödder B, et al. 236
- Gagliano M, see Gebbia N, et al. 26
 Gebbia N, Leto G, Gagliano M, Tumminello FM, Rausa L: Lysosomal alterations in heart and liver of mice treated with doxorubicin 26
 Germain JSt, see Dufour M, et al. 125
 Gibb J, see Perez DJ, et al. 278
 Gilchrist NL, Caldwell J, Watson ID, Cunningham D, Forrest GJ, Soukup M, Stewart M, Fitch W: Comparison of serum and cerebrospinal fluid levels of methotrexate in man during high-dose chemotherapy for aggressive non-Hodgkin's lymphoma 290
 Gill PG, see Reece PA, et al. 295
 Gordon C, see Perez DJ, et al. 278
 Green SJ, see Edmonson JH, et al. 181
 Groth S, see Sørensen, JB, et al. 97
 Gutierrez PL, Cohen BE, Sosnovsky G, Davis TA, Egorin MJ: On the search for new anticancer drugs. 14: The plasma pharmacokinetics and tissue distribution of spin-labeled thio-TEPA (SL-O-TT) 185
- Halbert GW, Stuart JFB, Florence AT: A low density lipoprotein-methotrexate covalent complex and its activity against L 1210 cells in vitro 223
 Hansen HH, see Sørensen JB, et al. 97
 Hansen SW, see Sørensen JB, et al. 97
 Harland SJ, see Waxman JH, et al. 171
 Hartmann, HR, Bollag W: The effects of arachinoids on rat mammary carcinogenesis 141
 Hecquet B, Vennin P, Fournier C, Lefebvre JL, Caty A, Bonneterre J, Adenis L, Demaille A: Platinum concentration in human tumors of head and neck, uterine cervix, and breast following treatment with cisplatin 310
 Heier M, see Fossá SD, et al. 161
 Heimer R, see Danhauser LL, et al. 214
 Herrera L, see Wilking N, et al. 300
 Hersh M, see Weiss GR, et al. 144
 Hillen HFP, see Wagener DJTh, et al. 86
 Hocke C, see Bui NB, et al. 82
 Hoel R, see Fossá SD, et al. 161
 Hoff DD von, see Weiss GR, et al. 144
 Hoogendoorn GJ, see Wagener DJTh, et al. 86
 Hoshino A, see Kojima T, et al. 268
 Hirshikeshavan HJ, see Ardalani B, et al. 44
 Hutcheon AH, see Cunningham D, et al. 303
- Iguchi H, Tone H, Ishikura T, Takeuchi T, Umezawa H: Pharmacokinetics and disposition of 4'-O-tetrahydropyranyladriamycin in mice by HPLC analysis 132
 Iida H, see Tsuruo T, et al. 16
 Inoue K, Mukaiyama T, Mitsui I, Ogawa M: In vitro evaluation of anticancer drugs in relation to development of drug resistance in the human tumor clonogenic assay 208
 Ishikura T, see Iguchi H, et al. 132
 Ishizawa M, see Iwamoto Y, et al. 228
 Ito Y, see Kojima T, et al. 268
 Iturrain M, see Vorobiof DA, et al. 253
 Iven H, Brasch H, Engster J: Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits 115
- Iwamoto Y, Kawano T, Ishizawa M, Aoki K, Kuroiwa T, Baba T: Inactivation of *cis*-diamminedichloroplatinum (II) in blood and protection of its toxicity by sodium thiosulfate in rabbits 228
 Jacobsen SJ, see Page T, et al. 59
 James C, see Pinkerton CR, et al. 258
 Jinks S, see Millar BC, et al. 307
 Jungclas H, see Danigel H, et al. 121
 Kamiya O, see Kojima T, et al. 268
 Kawabata N, see Tsuruo T, et al. 16
 Kawano T, see Iwamoto Y, et al. 228
 Kaye SB, see Cunningham D, et al. 303
 Kelson D, see Casper ES, et al. 233
 Khan AA, see Rao PN, et al. 20
 Kinoshita T, see Kojima T, et al. 268
 Kisner DL, see Weiss GR, et al. 144
 Kitatani Y, see Tsuruo T, et al. 16
 Kojima T, Hoshino A, Ohara K, Kamiya O, Nagata K, Ito Y, Kinoshita T, Sugiyama I, Yamada M, Sato H, Nagura E, Dohke Y: The effects of multiple combination chemotherapy with vinorelbine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer 268
 Kovach JS, see Buck M, et al. 40
 Kovach JS, Buck M, Tsukamoto T, Odegaard A, Lieber MM: Regional targeting of Bisantrene by directed intravascular precipitation 192
 Kuhn JG, see Weiss GR, et al. 144
 Kuperminc M, see Ellis ME, et al. 174
 Kuroiwa T, see Iwamoto Y, et al. 228
 Landbeck G, see Erttmann R, et al. 101
 Lefebvre JL, see Hecquet B, et al. 310
 Lele SB, see Pendyala L, et al. 203
 Lelieveld P, Middeldorp RJF, van Putten LM: Effectiveness of *P*-aminobenzoyl-O-phenylenediamine (Goe 1734) against mouse, rat, and human tumour cells 88
 Leto G, see Gebbia N, et al. 26
 Lieber MM, see Kovach JS, et al. 192
 Lilly MB, Omura GA: Clinical pharmacology of oral intermediate-dose methotrexate with or without probenecid 220
 Lister TA, see Waxman JH, et al. 171
 Litterst CL, see Uozumi J, et al. 93
 Loeb M, see Fossá SD, et al. 161
 Long HJ, see Edmonson JH, et al. 181
 Lotzova E, see Rao NP, et al. 20
 Lucie N, see Cunningham D, et al. 303
 Ludden TM, see Weiss GR, et al. 144
 Madajewicz S, see Pendyala L, et al. 203
 Malpas JS, see Waxman JH, et al. 171
 Mangum JH, see Page T, et al. 59
 Maraminchil D, see Bertault-Pérès P, et al. 76
 Margolese R, see Panasci L, et al. 164
 McCormick M, see Morton RP, et al. 283
 McGovern MR, see Miller K, et al. 49
 Mead GM, Williams CJ, Whitehouse JM: Cisplatin, adriamycin and cyclophosphamide (PACe) combination chemotherapy in patients with ovarian carcinoma resistant to chlorambucil 179
 Meunier B, see Bernadou J, et al. 63
 Michel C, see Canal P, et al. 149
 Mickey DD: Combined therapeutic effects of an immunomodulator, PSK, and chemotherapy with carboquone on rat bladder carcinoma 54
 Middeldorp RJF, see Lelieveld P, et al. 88
 Millar BC, Siddiq ZH, Millar JL, Jinks S: Mesna does not reduce cisplatin induced nephrotoxicity in the rat 307
 Millar JL, see Millar BC, et al. 307
 Miller K, McGovern RM, Ames MM: Effect of a hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines 49

- Mitsui I, see Inoue K, et al. 208
 Mittelman A, see Caspar ES, et al. 233
 Mittelman A, see Wilking N, et al. 300
 Mödder B, Fütterer G: Protective effect of testosterone on 5 β -dihydrotestosterone pretreatment on CFU-E numbers in busulfan-treated rabbits 236
 Monserrat B, see Bernadou J, et al. 63
 Mølgård K, see Wassermann K, et al. 244
 Moore JV: Clonogenic response of cells of murine intestinal crypts to 12 cytotoxic drugs 11
 Moore JV: Dose-response curves after in vivo experimental chemotherapy: Influence of route of administration in biological outcomes 91
 Morton RP, Rugman F, Dorman EB, Stoney PJ, Wilson JA, McCormick M, Veevers A, Stell PM: Cisplatin and Bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial 283
 Muggia FM: Testicular cancer and the legacy of chemotherapy 1
 Mukaiyama T, see Inoue K, et al. 208
 Nagata K, see Kojima T, et al. 268
 Nagumo N, see Tsuruo T, et al. 16
 Nagura E, see Kojima T, et al. 268
 Newlands ES, see Brindley CJ, et al. 66
 Ninane J, Baurain R, de Selys A, Trouet A, Cornu G: High dose melphalan in children with advanced malignant disease. A pharmacokinetic study 263
 Nissen MH, see Sørensen JB, et al. 97
 Nyhan WL, see Page T, et al. 59
 Odegaard A, see Kovach JS, et al. 192
 Ogawa M, see Inoue K, et al. 208
 Ohara K, see Kojima T, et al. 268
 Omura GA, see Lilly MB, et al. 220
 Ordway FS, see Schilsky RL, et al. 272
 Page T, Jacobsen SJ, Smejkal RM, Scheele J, Nyhan WL, Mangum JH, Robins RK: Studies on the mechanism of cytotoxicity of 3-deazaguanosine in human cancer cells 59
 Panasci LC, see Dufour M, et al. 125
 Panasci L, Ford J, Margolese R: A phase II study of sequential methotrexate and fluorouracil in advanced colorectal cancer 164
 Paolletti C, see Bernadou J, et al. 63
 Pendyal L, Madajewicz S, Lele SB, Arbuck SG, Creaven PJ: Evaluation of the nephrotoxicity of iproplatin (CHIP) in comparison to cisplatin by the measurement of urinary enzymes 203
 Perez DJ, Powles TJ, Smith IE, Vincent MD, Ashley S, Gordon C, Gibb J, Clarke S, Coombes RC: The modulating effects of flurbiprofen on adriamycin plus vincristine or vindesine in the treatment of advanced breast cancer 278
 Peterson C, see Beksac M, et al. 72
 Petrelli N, see Wilking N, et al. 300
 Pflüger KH, see Danigel H, et al. 121
 Pinkerton CR, Rogers H, James C, Bowman A, Barbor PRH, Eden OB, Pritchard J: A phase II study of ifosfamide in children with recurrent solid tumours 258
 Pirtle III TE, see Weiss GR, et al. 144
 Ploeg E van der, see Veelen H van, et al. 167
 Powles T, see Waxman JH, et al. 171
 Powles TJ, see Perez DJ, et al. 278
 Pritchard J, see Pinkerton CR, et al. 258
 Putten LM van, see Lelieveld P, et al. 88
 Ramu A, Fridkin M, Steinherz R: Cross resistance to esters of methotrexate in a doxorubicin-resistant subline of P388 murine leukemia 31
 Rao PN, Wang Y-C, Lotzova E, Khan AA, Rao SP, Stephens LC: Antitumor effects of gossypol on murine tumors 20
 Rao SP, see Rao PN, et al. 20
 Rausa L, see Gebbia N, et al. 26
 Reece PA, Stafford I, Russell J, Gill PG: Nonlinear renal clearance of ultrafilterable platinum in patients treated with *cis*-dichlorodiammineplatinum (II) 295
 Reizenstein P, see Beksac M, et al. 72
 Richardson RL, see Edmonson JH, et al. 181
 Riggs Jr CE, see Dodion P, et al. 153
 Robins RK, see Page T, et al. 59
 Roche H, see Bernadou J, et al. 63
 Roche H, see Canal P, et al. 149
 Rogers HJ, see Adam AM, et al. 176
 Rogers H, see Pinkerton CR, et al. 258
 Rørth M, see Sørensen JB, et al. 97
 Rosowsky A, see Brownman GB, et al. 111
 Rugman F, see Morton RP, et al. 283
 Russell J, see Reece PS, et al. 295
 Sakurai Y, see Tsuruo T, et al. 16
 Sato H, see Kojima T, et al. 268
 Scheele J, see Page T, et al. 59
 Scheerder H, see Wagener DJTh, et al. 86
 Schilsky RL, Ordway FS: Insulin effects on methotrexate polyglutamate synthesis and enzyme binding in cultured human breast cancer cells 272
 Schmidt L, see Danigel H, et al. 121
 Seidenfeld J: Effects of difluoromethylornithine on proliferation, polyamine content and plating efficiency of cultured human carcinoma cells 196
 Selys A de, see Ninane J, et al. 263
 Siddik ZH, see Millar BC, et al. 307
 Sleijfer DT, see Veelen H van, et al. 167
 Sluiter WJ, see Veelen H van, et al. 167
 Smejkal RM, see Page T, et al. 59
 Smith IE, see Perez DJ, et al. 278
 Smith SD, see Cohen PS, et al. 6
 Sørensen JB, Groth S, Hansen SW, Nissen MH, Rørth M, Hansen HH: Phase I study of the cisplatin analogue 1,1-diammino-methylcyclohexane sulfatoplatinum (TNO-6) (NSC 311056) 97
 Sosnovsky G, see Gutierrez PL, et al. 185
 Soukop M, see Gilchrist NL, et al. 290
 Soukop M, see Cunningham D, et al. 303
 Soula G, see Canal P, et al. 149
 Spiegel P, see Brownman GP, et al. 105
 Spiegel P, see Brownman GP, et al. 111
 Stack BR, see Cunningham D, et al. 303
 Stafford I, see Reece PA, et al. 295
 Steiness E, see Wassermann K, et al. 244
 Steinherz R, see Ramu A, et al. 31
 Stell PM, see Morton RP, et al. 283
 Stephens LC, see Rao PN, et al. 20
 Stevenson RD, see Cunningham D, et al. 303
 Stewart M, see Gilchrist NL, et al. 290
 Stoney PJ, see Morton RP, et al. 283
 Stringfellow DA, see Catino JJ, et al. 240
 Stuart JFB, see Halbert GW, et al. 223
 Suguri, I, see Kojima T, et al. 268
 Takeuchi T, see Iguchi H, et al. 132
 Tamburini JM, see Dodion P, et al. 153
 Tansey P, see Cunningham D, et al. 303
 Tone H, see Iguchi H, et al. 132
 Trouet A, see Ninane J, et al. 263
 Tsukagoshi S, see Tsuruo T, et al. 16
 Tsukamoto T, see Kovach JS, et al. 192
 Tsuruo T, Kawabata H, Nagumo N, Iida H, Kitatani Y, Tsukagoshi S, Sakurai Y: Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns 16
 Tumminello FM, see Gebbia N, et al. 26

- Umezawa H, see Iguchi H, et al. 132
Uozumi J, Litterst CL: The effect of cisplatin on renal ATPase activity and in vitro 93
- Vasanthakumar G, Ahmed NK: Uptake and metabolism of daunorubicin by human myelocytic cells 35
van Veelen H, Willemse PHB, Sleijfer DT, vander Ploeg E, Sluiter WJ, Doorenbos H: Mechanism of adrenal suppression by high-dose medroxyprogesterone acetate in breast cancer patients 167
Veevers A, see Morton RP, et al. 283
van der Vegt SGL, see Wagener DJTh, et al. 86
Vennin P, see Hecquet B, et al. 310
Vincent MD, see Perez DJ, et al. 278
Vorobiof DA, Iturralde M, Falkson G: Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone 253
- Wagener DJTh, Yap SH, Wobbes T, Burghouts JTM, van Dam FE, Hillen HFP, Hoogendoorn GJ, Scheerder H, van der Vegt SGL: Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) in advanced gastric cancer 86
Wang YC, see Rao PN, et al. 20
- Wassermann K, Mølgaard K, Steiness E: Similar changes in cardiac morphology and DNA synthesis induced by doxorubicin and 4'-epi-doxorubicin 244
Watson ID, see Gilchrist NL, et al. 290
Waxman JH, Harland SJ, Coombes RC, Wrigley PFM, Malpas JS, Powles T, Lister TA: The treatment of postmenopausal women with advanced breast cancer with buserelin 171
Weiss GR, Hersh M, Kuhn JG, Ludden TM, von Hoff DD, Kisner DL, Pirtle III TE: A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer 144
Weiss RB, see Ellis ME, et al. 174
Whitehouse JM, see Mead GM, et al. 179
Wilking N, Petrelli N, Herrera L, Mittelman A: Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal 300
Willemse PHB, see van Veelen H, et al. 167
Williams CJ, see Mead GM, et al. 179
Wilson JA, see Morton RP, et al. 283
Wobbes T, see Wagener DJTh, et al. 86
Wrigley PFM, see Waxman JH, et al. 171
Yamada M, see Kojima T, et al. 268
Yap SH, see Wagener DJTh, et al. 86
Young CW, see Casper ES, et al. 233



Subject index – Volume 15

- ACTH(Synacthen) stimulation 167
Adriamycin (ADM) 132, 278
Amino acid 125
(α S,SS)-2 Amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid 44
Aminoglutethimide 176
Anthracyclines 153
Antifolates 111
Antitumor activity 54
- drugs 16
- effects 20
Arotinoids 141
- Biliary metabolites 63
Bisantrene 40, 192
- pharmacokinetics 144
Bleomycin 283
Blood urea 307
Bone marrow cells 125
Breast cancer 167, 171, 268
Buserelin 171
Busulfan 236
- Calcium antagonists 16
Carboquone 54
Carcinogenesis 141
Cardiotoxicity 253
Cell proliferation 196
Cerebrospinal fluid levels 290
Chemotherapy 1, 6, 91, 283, 290
Children 258, 263
Cis-dichlorodiammine-platinum(II) 228, 295
Cisplatin 93, 183, 283, 307, 310
- analogue 97
Colorectal cancer 161, 164
Combination
- CYVADIC 82
- FAP 86
- chemotherapy 179, 181, 268
- therapy 300
Comparative study 132
Cyclosporin A 76
Cytotoxic drugs 11
Cytotoxicity 125
CYVADIC combination 82
- Daunorubicin 35
Dezaguanosine 59
Difluoromethylornithine 196
Disposition in vivo 132
DNA synthesis 244
Doxifluridine 161
Doxorubicin 26, 31, 244
Drug resistance 31, 208
- Ellipticine 63
4'-Epidoxorubicin 253
Etoposide 66, 121
- FAP combination 86
Fermentation screening 240
Fludarabine 233
Fluorometric assay 40
Fluorouracil 164, 214
5-Fluorouracil 44
Flurbiprofen 278
- Gastric cancer 86
Goe 1734 88
Gestational chorio-carcinoma 66
Gossypol 20
- Head and neck cancer 283
Hepatic arterial infusion 144
Hexamethylmelamine 49
High-dose MTX therapy 101
HPLC analysis 132
Human
- cancer cells 59
- cell lines 49
- tumors 310
- tumor clonogenic assay 208
7-Hydroxy-methotrexate 101
- Ifosfamide 258
Inactivation 228
Insulin 272
Intestinal clonogenic cells 11
In vitro antitumor activity 208
Iproplatin 203
- Kinetics in man 101
- L1210 cells 223
Leucovorin 105, 111, 214
Leukemic cells 72
Liquid chromatography 121
Lomustine 174
Lung cancer 303
- Malignant ascites 149
- teratoma 66
Mass spectrometry 121
Medroxyprogesterone acetate 167
Melphalan 125, 263
Mesna 307
Metabolism 35, 153
Methotrexate 31, 105, 115, 164, 214, 220, 223, 290
- analogs 31
- metabolism 272
Metyrapone stimulation 167
Microtiter cytotoxicity 240
Mitoxantrone 253
MPA 167
Murine tumors 20
Myelocytic cells 35
- Nephrotoxicity 174, 203, 307
New drug 88
Non-Hodgkin's lymphoma 290
- 1,10-Orthophenanthroline 6
Ovarian carcinoma 149, 179
- Pharmacokinetics 66, 76, 115, 132, 149, 183, 185, 263
Phase I study 97
P388 leukemia 44
P388 murine leukemia 31

VIII

Polyamines	196	
Postmenopausal women	167	
Protection	236	
PSK	54	
Renal ATPase	93	
Sarcoma	181	
Sodium thiosulfate	228	
Soft tissue sarcomas	82	
Solid tumors	258	
Squamous carcinoma	283, 300	
Teniposide	149	
Testicular cancer	1	
Testosterone	236	
4'-O Tetrahydropyranyl-		
adriamycin (THP)	132	
thio-TEPA	185	
TNO-6	97	
Vinca alkaloids	72	
Vincristine	278	
Vindesine	278	
VP16	303	

